Skip to main content
Erschienen in: Drugs & Aging 2/2007

01.02.2007 | Original Research Article

Evolution of Medication Use in Jerusalem Elders

Results from the Jerusalem Longitudinal Study

verfasst von: Dr Michael A. Steinman, Yoram Maaravi, Louise C. Walter, Robert Hammerman-Rozenberg, Jochanan Stessman

Erschienen in: Drugs & Aging | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

While overall rates of medication use have been increasing over time, less is known about how medication use changes within individuals as they age.

Objective

The aim of this study was to evaluate changes in medication use and predictors of medication accrual among community-dwelling elders followed for a 7-year period, from age 70 ± 1 years to age 77 ± 1 years.

Methods

The study was a community-based, longitudinal, cohort study. The study group consisted of 280 patients from the Jerusalem Longitudinal Study, a population-based sample of Jerusalem residents born in 1920–1 who underwent extensive evaluation in 1990–1 and again in 1997–8. The main outcome measure of the study was the change in the total number of medications taken between baseline and follow-up. Medication use was assessed by home interviews.

Results

Half of the sample were men. Medication use more than doubled over the 7-year study period, from a mean of 2.0 to 5.3 medications per patient (p < 0.001), and 57 patients (20%) increased their total drug use by six or more medications. Vitamins, minerals and cardiovascular medications were the most commonly prescribed medications at follow-up, and accounted for approximately half of the total increase in medication use. On multivariable logistic regression analyses, decline in self-rated health was the strongest predictor of above-median increases in medication use (odds ratio [OR] 3.2; 95% CI 1.8, 6.2). The only nonclinical predictor of above-median increases in medication use was good social engagement at baseline (OR 1.8; 95% CI 1.1, 3.1).

Conclusion

Medication use in Jerusalem elders grew rapidly over the 1990s, more than doubling in volume over a 7-year period. While health status was the factor most strongly predictive of the degree of change, the magnitude of increase for elders as a whole suggests major changes in prescribing practices over this interval.
Literatur
1.
Zurück zum Zitat Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med 2004; 164: 1957–9PubMedCrossRef Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med 2004; 164: 1957–9PubMedCrossRef
2.
Zurück zum Zitat Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004; 52: 1349–54PubMedCrossRef Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004; 52: 1349–54PubMedCrossRef
4.
Zurück zum Zitat Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004; 38: 303–12PubMed Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004; 38: 303–12PubMed
5.
Zurück zum Zitat Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med 2001; 16: 793–9PubMedCrossRef Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med 2001; 16: 793–9PubMedCrossRef
6.
Zurück zum Zitat Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55: 809–17PubMedCrossRef Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55: 809–17PubMedCrossRef
7.
Zurück zum Zitat Stewart RB, Moore MT, May FE, et al. A longitudinal evaluation of drug use in an ambulatory elderly population. J Clin Epidemiol 1991; 44: 1353–9PubMedCrossRef Stewart RB, Moore MT, May FE, et al. A longitudinal evaluation of drug use in an ambulatory elderly population. J Clin Epidemiol 1991; 44: 1353–9PubMedCrossRef
8.
Zurück zum Zitat Jylha M. Ten-year change in the use of medical drugs among the elderly: a longitudinal study and cohort comparison. J Clin Epidemiol 1994; 47: 69–79PubMedCrossRef Jylha M. Ten-year change in the use of medical drugs among the elderly: a longitudinal study and cohort comparison. J Clin Epidemiol 1994; 47: 69–79PubMedCrossRef
9.
Zurück zum Zitat Chrischilles EA, Foley DJ, Wallace RB, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol 1992; 47: M137–44PubMedCrossRef Chrischilles EA, Foley DJ, Wallace RB, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol 1992; 47: M137–44PubMedCrossRef
10.
Zurück zum Zitat Lernfelt B, Samuelsson O, Skoog I, et al. Changes in drug treatment in the elderly between 1971 and 2000. Eur J Clin Pharmacol 2003; 59: 637–44PubMedCrossRef Lernfelt B, Samuelsson O, Skoog I, et al. Changes in drug treatment in the elderly between 1971 and 2000. Eur J Clin Pharmacol 2003; 59: 637–44PubMedCrossRef
11.
Zurück zum Zitat Veehof L, Stewart R, Haaijer-Ruskamp F, et al. The development of polypharmacy. A longitudinal study. Fam Pract 2000; 17: 261–7PubMedCrossRef Veehof L, Stewart R, Haaijer-Ruskamp F, et al. The development of polypharmacy. A longitudinal study. Fam Pract 2000; 17: 261–7PubMedCrossRef
12.
Zurück zum Zitat Stuart B, Coulson NE. Dynamic aspects of prescription drug use in an elderly population. Health Serv Res 1993; 28: 237–64PubMed Stuart B, Coulson NE. Dynamic aspects of prescription drug use in an elderly population. Health Serv Res 1993; 28: 237–64PubMed
13.
Zurück zum Zitat Kouzis AC, Eaton WM. Absence of social networks, social support, and health services utilization. Psychol Med 1998; 28: 1301–10PubMedCrossRef Kouzis AC, Eaton WM. Absence of social networks, social support, and health services utilization. Psychol Med 1998; 28: 1301–10PubMedCrossRef
14.
Zurück zum Zitat Stessman J, Ginsberg G, Maaravi Y, et al. Profile of Jerusalem’s 70 year olds: medical data. Isr J Med Sci 1996; 32: 665–87PubMed Stessman J, Ginsberg G, Maaravi Y, et al. Profile of Jerusalem’s 70 year olds: medical data. Isr J Med Sci 1996; 32: 665–87PubMed
15.
Zurück zum Zitat Stessman J, Cohen A, Ginsberg GM, et al. The Jerusalem seventy-year-old longitudinal study: I. Description of the initial cross-sectional survey. Eur J Epidemiol 1995; 11: 675–84PubMedCrossRef Stessman J, Cohen A, Ginsberg GM, et al. The Jerusalem seventy-year-old longitudinal study: I. Description of the initial cross-sectional survey. Eur J Epidemiol 1995; 11: 675–84PubMedCrossRef
16.
Zurück zum Zitat Yang JC, Tomlinson G, Naglie G. Medication lists for elderly patients: clinic-derived versus in-home inspection and interview. J Gen Intern Med 2001; 16: 112–5PubMedCrossRef Yang JC, Tomlinson G, Naglie G. Medication lists for elderly patients: clinic-derived versus in-home inspection and interview. J Gen Intern Med 2001; 16: 112–5PubMedCrossRef
17.
Zurück zum Zitat Cohen A, Stessman J, Ginsberg GM, et al. The Jerusalem seventy year olds longitudinal study: II. Background results from the initial home interview. Eur J Epidemiol 1995; 11: 685–92PubMedCrossRef Cohen A, Stessman J, Ginsberg GM, et al. The Jerusalem seventy year olds longitudinal study: II. Background results from the initial home interview. Eur J Epidemiol 1995; 11: 685–92PubMedCrossRef
18.
Zurück zum Zitat Cohen A, Ginsberg G, Friedman R, et al. Profile of Jerusalem’s 70 year olds: social data. Isr J Med Sci 1996; 32: 688–701PubMed Cohen A, Ginsberg G, Friedman R, et al. Profile of Jerusalem’s 70 year olds: social data. Isr J Med Sci 1996; 32: 688–701PubMed
20.
Zurück zum Zitat Fillenbaum GG, Horner RD, Hanlon JT, et al. Factors predicting change in prescription and nonprescription drug use in a community-residing black and white elderly population. J Clin Epidemiol 1996; 49: 587–93PubMedCrossRef Fillenbaum GG, Horner RD, Hanlon JT, et al. Factors predicting change in prescription and nonprescription drug use in a community-residing black and white elderly population. J Clin Epidemiol 1996; 49: 587–93PubMedCrossRef
21.
Zurück zum Zitat Sax P. Expenditure and consumption of medicines in Israel 1975–85: analysis of trends and elements of growth. Isr J Med Sci 1988; 24: 307–16PubMed Sax P. Expenditure and consumption of medicines in Israel 1975–85: analysis of trends and elements of growth. Isr J Med Sci 1988; 24: 307–16PubMed
22.
Zurück zum Zitat Sax P. Recent trends in drug utilization in Israel. Isr J Med Sci 1992; 28: 718–25PubMed Sax P. Recent trends in drug utilization in Israel. Isr J Med Sci 1992; 28: 718–25PubMed
23.
Zurück zum Zitat Sax P. Spending on medicines in Israel in an international context. Isr Med Assoc J 2005; 7: 286–91PubMed Sax P. Spending on medicines in Israel in an international context. Isr Med Assoc J 2005; 7: 286–91PubMed
24.
Zurück zum Zitat Fuchs Z, Novikov I, Blumstein T, et al. Patterns of drug use among the community-dwelling old-old population in Israel. Isr Med Assoc J 2003; 5: 346–51PubMed Fuchs Z, Novikov I, Blumstein T, et al. Patterns of drug use among the community-dwelling old-old population in Israel. Isr Med Assoc J 2003; 5: 346–51PubMed
25.
Zurück zum Zitat Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151: 1825–32PubMedCrossRef Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151: 1825–32PubMedCrossRef
26.
Zurück zum Zitat Shah S, Cook DG. Inequalities in the treatment and control of hypertension: age, social isolation and lifestyle are more important than economic circumstances. J Hypertens 2001; 19: 1333–40PubMedCrossRef Shah S, Cook DG. Inequalities in the treatment and control of hypertension: age, social isolation and lifestyle are more important than economic circumstances. J Hypertens 2001; 19: 1333–40PubMedCrossRef
27.
Zurück zum Zitat Hawkley LC, Cacioppo JT. Loneliness and pathways to disease. Brain Behav Immun 2003; 17Suppl. 1: S98–105PubMedCrossRef Hawkley LC, Cacioppo JT. Loneliness and pathways to disease. Brain Behav Immun 2003; 17Suppl. 1: S98–105PubMedCrossRef
28.
Zurück zum Zitat Berkman LF. Assessing the physical health effects of social networks and social support. Ann Rev Public Health 1984; 5: 413–32CrossRef Berkman LF. Assessing the physical health effects of social networks and social support. Ann Rev Public Health 1984; 5: 413–32CrossRef
29.
Zurück zum Zitat Fillenbaum GG, Hanlon JT, Corder EH, et al. Prescription and nonprescription drug use among black and white community-residing elderly. Am J Public Health 1993; 83: 1577–82PubMedCrossRef Fillenbaum GG, Hanlon JT, Corder EH, et al. Prescription and nonprescription drug use among black and white community-residing elderly. Am J Public Health 1993; 83: 1577–82PubMedCrossRef
30.
Zurück zum Zitat Al-Windi A. Determinants of medicine use in a Swedish primary health care practice population. Pharmacoepidemiol Drug Saf 2005; 14: 47–51PubMedCrossRef Al-Windi A. Determinants of medicine use in a Swedish primary health care practice population. Pharmacoepidemiol Drug Saf 2005; 14: 47–51PubMedCrossRef
31.
Zurück zum Zitat Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9PubMedCrossRef Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9PubMedCrossRef
32.
Zurück zum Zitat Cott CA, Gignac MA, Badley EM. Determinants of self rated health for Canadians with chronic disease and disability. J Epidemiol Community Health 1999; 53: 731–6PubMedCrossRef Cott CA, Gignac MA, Badley EM. Determinants of self rated health for Canadians with chronic disease and disability. J Epidemiol Community Health 1999; 53: 731–6PubMedCrossRef
Metadaten
Titel
Evolution of Medication Use in Jerusalem Elders
Results from the Jerusalem Longitudinal Study
verfasst von
Dr Michael A. Steinman
Yoram Maaravi
Louise C. Walter
Robert Hammerman-Rozenberg
Jochanan Stessman
Publikationsdatum
01.02.2007
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 2/2007
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724020-00005

Weitere Artikel der Ausgabe 2/2007

Drugs & Aging 2/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.